NEUROINMUNOLOGÍA
Queen Mary University of London
Londres, Reino UnidoPublicaciones en colaboración con investigadores/as de Queen Mary University of London (2)
2019
-
Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial
The Lancet Neurology, Vol. 18, Núm. 9, pp. 845-856
2009
-
Safety and immunogenicity of a new formulation of interferon β-1a (Rebif® New Formulation) in a Phase IIIb study in patients with relapsing multiple sclerosis: 96-week results
Multiple Sclerosis, Vol. 15, Núm. 2, pp. 219-228